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Key Points
• IST leads to a response
in nearly half, and to
RBC transfusion
independence in about
a third, of selected
lower-risk MDS patients.
•Hypocellularity of bone
marrow and the use of
horse ATG plus cyclo-
sporine are associ-
ated with increased
rates of transfusion
independence.
Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are
limited by small numbers and their single-center nature, and report conﬂicting data regarding
predictors for response to IST. We examined outcomes associated with IST and predictors of
beneﬁt in a large international cohort of patientswithMDS.Datawere collected from15 centers
in the United States and Europe. Responses, including red blood cell (RBC) transfusion
independence (TI), were assessed based on the 2006MDS InternationalWorkingGroup criteria,
and overall survival (OS) was estimated by Kaplan-Meier methods. Logistic regression models
estimated odds for response and TI, and Cox Proportional Hazard models estimated hazards
ratios forOS.We identiﬁed207patientswithMDSreceiving IST, excludingsteroidmonotherapy.
Themost common IST regimen was anti-thymocyte globulin (ATG) plus prednisone (43%).
Overall response rate (ORR) was 48.8%, including 11.2% (95% conﬁdence interval [CI],
6.5%-18.4%) who achieved a complete remission and 30% (95% CI, 22.3%-39.5%) who achieved
RBC TI. Median OS was 47.4 months (95% CI, 37-72.3 months) and was longer for patients who
achieved a response or TI. Achievement of RBC TI was associated with a hypocellular bone
marrow(cellularity, 20%); horse ATGplus cyclosporinewasmore effective than rabbit ATG or
ATG without cyclosporine. Age, transfusion dependence, presence of paroxysmal nocturnal
hemoglobinuria or large granular lymphocyte clones, and HLA DR15 positivity did not predict
response to IST. IST leads to objective responses in nearly half the selected patients with the
highest rate of RBC TI achieved in patients with hypocellular bone marrows.
Introduction
Patients with lower-risk myelodysplastic syndromes (LR-MDS), traditionally defined as low or intermediate-1
risk groups as stratified by the 1997 International Prognostic Scoring System (IPSS), are most often
treated with transfusions, erythropoiesis-stimulating agents (ESAs), lenalidomide, or hypomethylating
agents (HMAs), often primarily directed at alleviating transfusion needs.1 However, patients frequently
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experience either primary or secondary treatment failure to these
agents, after which therapeutic options are quite limited.1 Immuno-
suppressive therapy (IST) has been used in patients with LR-MDS,
based on the observation that a subset of these patients develops
cytopenias as a consequence of hyperactivated T cells, leading
to suppression of hematopoiesis similar to that seen in aplastic
anemia.2,3 In addition, concomitant autoimmune diseases are common
in MDS; in a recent study, 48% of patients with MDS had serological
or clinical evidence of an autoimmune disease, which was found
to be an independent marker for a worse prognosis.4 IST with anti-
thymocyte globulin (ATG),5-8 cyclosporine,9-11 or alemtuzumab,12 as
well as IST combinations of ATG with cyclosporine13-17 or etanercept,18
have all been studied in this context. Although some studies reported
clinical activity with IST, others were not able to confirm a benefit of
IST in unselected or older patients with MDS.19-21 However, most
studies published to date have included a small number of patients
andwere restricted to single-institution experiences, limiting their ability to
reliably identify predictors of response to IST.22 The goal of this study
was to use a large, multicenter international cohort to retrospectively
examine the clinical outcomes and to identify predictors of response and
overall survival (OS) for patients with MDS treated with IST.
Patients and methods
Data source and eligibility
Patients aged 16 years or older with pathologically confirmed
MDS, as defined by the 2008 World Health Organization (WHO)
criteria23 who were treated with IST at any time during their
disease course, were considered eligible for the study. Data from
patients who met eligibility criteria were collected retrospectively
for the period that spanned from 2006 to 2016. Seven centers
were in the United States, and 4 were in Europe. In addition, 4
centers from the EuropeanMDSRegistry (EUMDS) (Austria, Greece,
Poland, and Israel) contributed cases to the study. Types of IST
included ATG (rabbit and horse), cyclosporine, tacrolimus, predni-
sone, and alemtuzumab, and combinations of them. Patients treated
with prednisone or other steroids as monotherapy were excluded, as
steroid monotherapy is generally ineffective in MDS. Investigators at
each center collected data and reported responses in deidentified
datasets, which were later centrally combined and analyzed at the
coordinating center (Yale University). The study was approved by
the institutional review boards at participating institutions.
Variable and patient characteristics
Individual patient characteristics as well as disease characteristics,
including 2008 WHO subtype23 and MDS risk category per the
IPSS,24 revised IPSS (IPSS-R),25 WHO-based prognostic scoring
system,26 and LR-MDS Prognostic Scoring System,27 were col-
lected. Cytogenetic risk was classified according to the IPSS.24
We also collected information about the presence of paroxysmal
nocturnal hemoglobinuria (PNH) and large granular lymphocyte (LGL)
clones, HLA-DR15 positivity and the presence of mutations in TP53,
IDH1/2, ASXL1, and SF3B1 genes, as well as the specific IST used
and the treatments that preceded and/or succeeded IST.
Response criteria and survival
Responses were defined using the modified 2006 MDS International
Working Group criteria.28 Red blood cell (RBC) transfusion in-
dependence (TI) was defined as the patient’s ability to maintain a
hemoglobin level $8 g/dL for at least 6 weeks without any RBC
transfusion support after being transfusion dependent before. OS was
measured from time of initiation of IST until death or last follow-up.
Statistical analysis
Descriptive statistics were calculated to characterize the study
cohort. We used Student t test and x2 test to compare continuous and
categorical variables, respectively. Kaplan-Meier methods estimated
OS from initiation of IST to death or end of follow-up. Univariate and
multivariate logistic regressionmodels estimated odds for response and
TI, and univariate and multivariate Cox proportional hazard models
estimated hazards ratios (HR) for OS. A stepwise procedure was used
to select each multivariate model. For each of the three multivariate
models, a group of candidate predictors with univariate Wald test P ,
.25 was selected for consideration in the final model. Within the
stepwise procedure for eachmodel, patients with missing data for any of
the candidate predictors were removed from the analysis, and no
imputation was conducted. All tests were 2-sided, with an a significance
level of 0.05. All analyses were performed using R version 3.3.2.29
Results
Study population
A total of 207 patients met study eligibility and were included.
Another 160 patients were excluded because they received steroid
monotherapy as their only therapy. Disease risk according to the
IPSS was low (22%), intermediate-1 (69%), or either intermediate-
2 or high risk (9%). Median age at diagnosis was 65 years (range,
15-95 years), and 63% were male (Table 1). Median white blood
cell count, hemoglobin level, and platelet count at time of IST initiation
were 2.43 109/L (range, 0.1-26.43 109/L), 8.9 g/dL (5.3-12.8 g/dL),
and 44.5 3 109/L (0-1111 3 109/L), respectively.
Sixty percent of patients had received a median of 1 other therapy
(range, 1-7) before IST. Prior treatments included the following
agents: ESAs (33%), HMAs (33%), thalidomide or lenalidomide
(9%), cytotoxic chemotherapy (11%), androgens (5%), and other
therapies including other IST, iron chelation therapy, and exper-
imental therapies (9%), either as mono or combination therapies.
Median follow-up time was 25.2 months (range, 0.5-245.1 months).
Patterns of treatment with IST
Of the 207 patients, IST regimens included several different
ATG-based combinations (76%), as well as cyclosporine (13%)
tacrolimus (4%) and others (7%). Combination regiments with
ATG as the backbone included ATG plus prednisone (43%), ATG
plus cyclosporine (21%), ATG plus tacrolimus (4%), and ATG plus
cyclosporine and etanercept (8%). ATG was given as the rabbit
isoform in 62% of patients and as horse isoform in 38% of
patients. Among patients who were reported to discontinue IST,
29.4% discontinued IST because of adverse effects, whereas
23.4%, 14.7%, 5.9%, and 17.6% discontinued IST because of
lack of response, disease progression, completion of treatment
regimen, or other reasons, respectively.
Response to IST therapy and predictors
Of 125 patients whose response data were recorded (Table 2),
11.2% (95%confidence interval [CI], 6.5%-18.4%) hadCR, 5.6% (95%
CI, 2.5%-11.6%) had PR, and 32% (95% CI, 24.1%-41%) achieved
HI, resulting in an ORR of 48.8% (95% CI, 39.8%-57.9%). In
contrast, 39.2% (95% CI, 30.7%-48.4%) of patients had stable
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disease, and 12% (95% CI, 7.1% to 19.3%) had progressive
disease. RBC TI was achieved in 30% (95% CI, 22.3%-39.5%) of
patients who were dependent on RBC transfusions before IST. For
patients who achieved RBC TI, the median time from initiation of
IST to TI was 9.4 weeks (95% CI, 6.3-12.6 weeks), and the median
duration of TI was 19.9 months (95% CI, 12.8-27 months).
In univariate analysis of predictors of response (CR1PR1HI), the
presence of SF3B1 mutation (reported in 10 of 73 patients who
had SF3B1 sequenced) was associated with a lower response
rate; however, it did not achieve statistical significance (mutated
vs nonmutated: OR, 0.2; 95% CI, 0.04-1.2; P 5 .08; Figure 1A).
In univariate analysis of predictors of TI, the receipt of IST as a
second or subsequent lines of treatment (any prior therapy vs no
prior therapy: OR, 0.5; 95% CI, 0.2-0.9; P 5 .048) was associated
with decreased odds of achieving TI. On the contrary, a hypocellular
bone marrow (,20% vs$20%: OR, 3.3; 95%CI, 1.1-10; P5 .03),
horse ATG (horse vs rabbit ATG: OR, 2.7; 95% CI, 1.03-7.2;
P 5 .043), and ATG plus cyclosporine (vs all other treatment
regimens: OR, 2.5; 95% CI, 1.1-6.0; P5 .048) were all significantly
associated with achievement of TI (Figure 1B).
In multivariate analysis of predictors of response, no predictive
factors for response were identified. In multivariate analysis of
predictors of TI, only a hypocellular bone marrow remained a significant
predictor of achieving RBC TI (,20% vs .20%: OR, 4.0; 95% CI,
1.2-13; P 5 .03). Age, prior transfusion dependence, MDS risk
scores, presence of a PNH or LGL clone, and HLA DR15 positivity
were not predictive of response with IST.
Overall survival after IST treatment and predictors
Median OS from time of IST initiation for all patients was 47.4 months
(95% CI, 37-72.3 months; Figure 2A). For patients who achieved a
response (CR1PR1HI) to IST, the median OS was not reached (95%
CI, 52.1 months-not reached), whereas patients without a response had
a median OS of 27.7 months (95% CI, 22.8-49.1 months; P 5 .0009)
(Figure 2B). Similarly, for patients who achieved TI with IST, median OS
was not reached (95%CI, 76.9 months-not reached), whereas patients
who remained transfusion-dependent had a median OS of 26.6 months
(95% CI, 20.9-46.6 months; P 5 .0002; Figure 2C).
In univariate analysis of predictors of OS, higher-risk IPSS score
predicted worse OS (HR, 1.8; 95% CI, 1.1-3.1; P 5 .02), whereas
low bone marrow blast percentage predicted improved OS (,5% vs
$5%; HR, 0.2; 95%CI, 0.1-0.4; P, .001; Figure 1C). In multivariate
analysis, a low bone marrow blast count (,5% vs $5%; HR, 0.2;
95% CI, 0.1-0.4; P , .0001) was a predictor of improved OS.
Discussion
To our knowledge, this is the largest reported cohort of patients with
MDS treated with IST. We observed that IST led to durable objective
responses in about half and to RBC TI in approximately one third of
Table 2. Response to IST
Response Percentage 95% CI
CR 11.2 6.5-18.4
PR 5.6 2.5-11.6
HI 32.0 24.1-41.0
SD 39.2 30.7-48.4
PD 12.0 7.1-19.3
ORR (CR1PR1HI) 48.8 39.8-57.9
TI 30 22.3-39.5
CR, complete response; HI, hematologic improvement; ORR, overall response rate;
PD, progressive disease; PR, partial response; SD, stable disease; TI, RBC transfusion
independence.
Table 1. Patient characteristics
Characteristic Median or N Range or %
Sex
Male 124 63.3%
Female 72 36.7%
Age, y 61 17-88
WHO subtype
RA 14 8.9%
RARS 8 5.1%
RCUD 5 3.2%
RCMD 93 59.2%
RAEB-1 15 9.6%
RAEB-2 5 3.2%
MDS-U 11 7.0%
Isolated 5q- 6 3.8%
Complete blood count
White blood cell count 2.4 0.1-26.4
Absolute neutrophil count 0.85 0-5.95
Hemoglobin level 8.9 5.3-12.8
Platelet count 44.5 0-1111
Bone marrow blast % 1.8 0-20
Bone marrow cellularity % 45 0-100
Hypocellular bone marrow (,20%) 22/82 26.8%
Peripheral blood blast % 0 0-3.3
IPSS
Low 33 22%
Intermediate-1 104 69.3%
Intermediate-2 12 8%
High 1 0.7%
LR-PSS
Risk category 1 38 25.3%
Risk category 2 62 41.3%
Risk category 3 50 33.3%
Molecular analysis
PNH clone (present/absent) (n = 62) 16/46 26%
LGL clone (present/absent) (n = 44) 16/28 36%
HLA-DR15 (positive/negative) (n = 52) 28/24 54%
TP53 (mutated/nonmutated) (n = 43) 2/41 5%
IDH1 (mutated/nonmutated) (n = 74) 2/72 3%
IDH2 (mutated/nonmutated) (n = 39) 0/39 0%
ASXL1 (mutated/nonmutated) (n = 41) 6/35 15%
SF3B1 (mutated/nonmutated) (n = 73) 10/63 14%
LR-PSS, LR-MDS Prognostic Scoring System.
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patients, which is in line with prior reports.22 Acknowledging the
limitations of selection bias of this retrospective experience and
cross-study comparisons, these response rates appear compara-
ble (or even slightly better) than other treatment modalities used for
patients with MDS with low and intermediate-1 IPSS risk including
ESAs, lenalidomide, and HMAs.30 ESAs result in HI in 30% to 50%
and lead to TI in about 20% to 40% of anemic unselected patients
with LR-MDS.31-34 In a minority of patients with deletion of the long
arm of chromosome 5 (5q-), lenalidomide results in HI in 56% to
76% and TI in in 26% of patients.35-37 However, in all other patients
A
Age,  60 vs. t 60 (n = 117)
Sex, Female vs. Male (n = 118)
Any Therapy Prior to IST vs. No Prior Therapy (n = 125)
ATG+Cyclosporin A vs. Other IST therapies (n = 124)
Bone marrow cellularity,  20% vs. t 20% (n = 77)
SF3B1 mutation, Present vs. Absent (n = 58)
PNH clone, Present vs. Absent (n = 52)
HLA-DR15, Present vs. Absent (n = 46)
Transfusion Dependent Prior to IST, Yes vs. No (n = 111)
Bone marrow blast,  5% vs. t 5% (n = 110)
IPSS score (n = 97)
Horse ATG vs. Rabbit ATG (n = 84)
OR (95% CI)
0.63 (0.30-1.32)
1.58 (0.73-3.41)
0.66 (0.33-1.32)
1.90 (0.81-4.47)
1.43 (0.52-3.94)
0.22 (0.04-1.21)
0.1 0.5 1 2 10
Odds ratio (95% CI)
2.25 (0.60-8.44)
1.19 (0.37-3.81)
1.06 (0.40-2.83)
2.26 (0.64-7.99)
0.94 (0.46-1.93)
1.48 (0.62-3.52)
B
Age,  60 vs. t 60 (n = 112)
Sex, Female vs. Male (n = 113)
Any Therapy Prior to IST vs. No Prior Therapy (n = 119)
ATG+Cyclosporin A vs. Other IST therapies (n = 119)
Bone marrow cellularity,  20% vs. t 20% (n = 71)
SF3B1 mutation, Present vs. Absent (n = 56)
PNH clone, Present vs. Absent (n = 47)
HLA-DR15, Present vs. Absent (n = 40)
Karyotype Risk IPSS, Good vs. Poor or Intermediate (n = 100)
Bone marrow blast, t 4% vs.  4% (n = 103)
IPSS score (n = 88)
Horse ATG vs. Rabbit ATG (n = 77)
OR (95% CI)
1.32 (0.59-2.96)
1.11 (0.48-2.55)
0.45 (0.20-1.00)
2.46 (1.00-6.06)
3.25 (1.09-9.67)
0.17 (0.02-1.46)
0.1 0.5 1 2 10
Odds ratio (95% CI)
1.48 (0.41-5.34)
1.80 (0.47-6.87)
2.11 (0.83-5.37)
0.49 (0.17-1.38)
0.77 (0.36-1.66)
2.73 (1.03-7.22)
Transfusion Dependent Prior to IST, Yes vs. No (n = 139)
C
Age,  60 vs. t 60 (n = 152)
Sex, Female vs. Male (n = 153)
Any Therapy Prior to IST vs. No Prior Therapy (n = 158)
ATG+Cyclosporin A vs. Other IST therapies (n =158)
Bone marrow cellularity,  20% vs. t 20% (n = 80)
SF3B1 mutation, Present vs. Absent (n = 70)
PNH clone, Present vs. Absent (n = 56)
HLA-DR15, Present vs. Absent (n = 51)
Bone marrow blast,  5% vs. d 5% (n = 135)
IPSS score (n = 113)
Horse ATG vs. Rabbit ATG (n = 102)
HR (95% CI)
0.64 (0.39-1.03)
0.63 (0.39-1.02)
1.50 (0.95-2.35)
0.91 (0.50-1.65)
1.17 (0.59-2.31)
0.38 (0.09-1.59)
0.1 0.5 1 2 10
Hazard ratio (95% CI)
0.62 (0.18-2.19)
1.16 (0.47-2.85)
1.13 (0.60-2.13)
0.23 (0.12-0.44)
1.85 (1.09-3.13)
1.99 (1.37-2.87)
Figure 1. Univariate analysis (forest plot) of clinical and molecular predictors of (A) response (CR1PR1HI), (B) achievement of TI, and (C) OS.
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without 5q-, lenalidomide leads to HI in 43% and TI in 26% of
patients.35,38,39 HMAs are more frequently used in higher-risk
patients with MDS (high and intermediate-2 IPSS risk), but
response rates in lower-risk patients with MDS have been
reported to be around 50%.40,41 However, several other papers
reported lower rates of response with HMAs.42,43
Not surprisingly, in our study, OS was significantly longer for
patients who achieved an objective response or TI, which is also
consistent with prior studies.13 Our results show, similar to the
aplastic anemia experience, that the use of horse ATG is superior
than rabbit ATG. Furthermore, although ATG has often be used
alone, our data suggest that the combination of horse ATG with
CSA seems to be the most effective form of IST. We were able to
confirm the predictive value of marrow hypocellularity for clinical
benefit of IST, but could not confirm it for any of the previously
reported variables.
Despite a clear benefit of IST in a subgroup of patients, IST is
infrequently used in clinical practice.1 This is partly because of
operational challenges in administering these drugs, which are
often given in the inpatient setting and can be associated with
severe reactions, and difficulties in predicting whether patients will
benefit from IST therapy. Several patient characteristics have been
identified as predictors of response to IST in prior studies. These
include younger age (,65 years) and limited prior transfusion
history (,2 years), as well as use as first-line treatment (or after
lenalidomide), low blast percentage with hypocellular marrow,
and good prognostic karyotype, in addition to HLA DR15
and PNH clone positivity and a higher CD81 terminal memory
T-cell percentage.5,6,44-46 On the basis of the patient’s age, the
duration of transfusion dependence before IST, and the HLA-
DR15 genotype, the National Institutes of Health response
model for IST in MDS was developed.44 However, reports have
varied widely in what characteristics predict response to IST,
and the National Institutes of Health response model could not
be validated in some studies.45,46
In our patient cohort, we were not able confirm the predictive value
of several previously described biomarkers of response. Age, prior
transfusion dependence, MDS risk assessment scores, presence
of PNH or LGL clones, HLA DR15 positivity, and gene mutations
did not appear to predict response to IST. Although we are not
able to explain these differences with certainty, this could be
related to several factors. These include potential selection bias
of which patients received IST and differences in interpretation of
variable positivity in the size of the PNH or LGL clone considered
positive by the local investigator. Furthermore, other differences
between the study cohorts regarding biologic factors that were
not controlled for might have played a role as well. In addition, the
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Figure 2. OS from onset of IST. (A) For all patients treated with IST. (B) According to response (CR1PR1HI) achieved vs no response achieved. (C) According to TI
achieved vs TI not achieved.
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limited number of data points for bone marrow cellularity as well as
HLA DR15 positivity and presence of a PNH clone could have
played a role as well. However, apart from the National Institutes
of Health cohort of patients,13,44 in most of the other studies examining
predictive factors for IST in MDS,5,6,45,47 bone marrow cellularity and
HLA DR15 status were assessed in only 10 to 20 patients,
whereas PNH clones were only tested for in less than 10 patients
if tested for at all. In comparison, in our study, in 70 to 80 patients,
data on bone marrow cellularity, and in 40 to 50 patients, data on
HLA DR15 and PNH clonal status was available to correlate with
response and OS.
In contrast, increased rates of TI were seen in patients with
hypocellular bone marrow (bone marrow cellularity,,20%), and
patients who were not exposed to any therapies before IST.
Furthermore, patients treated with horse ATG (compared with
rabbit ATG) had improved rates of TI in univariate analysis,
which has been described before in aplastic anemia.48 On the
contrary, one prior study in MDS reported no difference in the
response rate achieved with horse ATG vs rabbit ATG47;
however, this was a much smaller study of just 35 patients. In
addition, ATG in combination with cyclosporine was superior to
all other IST regimens examined regarding the achievement of TI
in univariate analysis, which is similar to studies in MDS45 and in
severe aplastic anemia.49
There are limited data regarding the effect of somatically recur-
rent genetic mutations on response to IST among patients with
MDS. Our analyses were limited to only five genes because these
genes were the ones most frequently reported by the centers,
and therefore these numbers allowed meaningful analyses, which
was not the case for the other recurrently mutated genes in MDS.
While providing important insights, such as any retrospective
study, our study has important limitations. Selection bias could
have inflated the benefit of IST, as the patients in the cohort were
selected by their treating physicians to receive IST. Missing
response or predictor data might have also affected the results
because of a lack of power or selection bias of ascertainment,
as we chose not to impute missing data, given the heterogeneity
of centers that supplied their data. MDS diagnosis and response to
therapy were reported by local investigators, and no centralized review
of bonemarrowbiopsy results and responseswas performed. However,
all local investigators are MDS experts with extensive experience in
hematopathology and in applying response MDS International Working
Group criteria, and the centers included in the study were tertiary
academic centers with extensive clinical and research history in the
management of MDS. In contrast, the fact that patients were treated in
specialized tertiary centers may also reduce the broad applicability of
these data to the general population. Although the disease pathology
was not centrally confirmed, exclusion of patients who received only
steroids would likely eliminated cases of MDS associated with
autoimmune or rheumatologic diseases; an association that has been
previously established.
In summary, in this large retrospective international cohort study
examining IST use in selected patients with LR-MDS, we found that
IST leads to durable objective responses in nearly half the selected
patients. Our results suggest the preferred IST regimen is horse
ATG in combination with CSA to be used in patients’ hypocellular
bone marrows.
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